Meyer R. Heyman

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Laparoscopic Splenectomy in Patients with Hematologic Diseases

John L. Flowers, Alan Kawarai Lefor, John Steers et al. · Annals of Surgery · 1996 · 151 citations

Medicine, Hematology, Surgery +6

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

Ashraf Badros, Olga Goloubeva, Aaron P. Rapoport et al. · Journal of Clinical Oncology · 2005 · 96 citations

Medicine, Pharmacology, Pharmacotherapy +17

Platelet transfusion therapy for the cancer patient.

Meyer R. Heyman, Charles A. Schiffer · PubMed · 1990 · 53 citations

Medicine, Hematology, Oncology +14

Phase I Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil (Cellcept) in Advanced Multiple Myeloma Patients

Naoko Takebe, Xiangfei Cheng, Suhlan Wu et al. · Clinical Cancer Research · 2004 · 44 citations

Medicine, Pharmacology, Pharmacotherapy +15